Time spent in glycaemic control with sustained body weight reduction with tirzepatide: A post hoc analysis of the <scp>SURPASS</scp> clinical trial programme
In this post hoc analysis, people with T2D experienced substantially longer continuous time in glycaemic control and more sustained body weight reductions with tirzepatide versus placebo and active comparators.
Authors
- Minzhi Liu (ORCID: https://orcid.org/0009-0009-7643-7122)
- Chrisanthi A. Karanikas (ORCID: https://orcid.org/0009-0008-0614-8264)
- Brandon K. Bergman
- Julio Rosenstock (ORCID: https://orcid.org/0000-0001-8324-3275)
- Vivian T. Thieu (ORCID: https://orcid.org/0000-0001-9803-4134)
- Yanyun Chen (ORCID: https://orcid.org/0009-0007-6327-7997)
- Rachel L. Batterham (ORCID: https://orcid.org/0000-0002-5477-8585)
- Palash Sharma (ORCID: https://orcid.org/0000-0003-3016-7541)
- W. Timothy Garvey
Institutions
- Eli Lilly (United States) (US)
- University of Alabama at Birmingham (US)
- Velocity Clinical Research (United States) (US)
- University College London (GB)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2025-03-13
- DOI
- https://doi.org/10.1111/dom.16337
- Citations
- 3
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 3.88
Funders
- American Diabetes Association
- Eli Lilly and Company
- European Foundation for the Study of Diabetes